HAL (France)open access
Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real‐world study
Nivolumab, 1, Relapse, Checkpoint inhibitor, Brentuximab vedotin, 0, Adolescent, Refractory
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 239056
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.